- |||||||||| Review, Journal: Advancements in the management of obesity: a review of current evidence and emerging therapies. (Pubmed Central) - Apr 30, 2024
Currently, orlistat, naltrexone/bupropion, glucagon-like peptide-1 receptor agonist (GLP-1 RA), and a few promising therapeutic agents are under investigation, including retatrutide, cagrilintide and orforglipron, which show promising weight reduction effects...Thus, it is important to approach obesity management holistically, considering individual needs and circumstances. In our opinion, consulting with healthcare professionals is crucial to developing a personalized plan that addresses both weight loss and overall health improvement.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Xenical (orlistat) / Roche, GSK
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective. (Pubmed Central) - Apr 29, 2024 Semaglutide 2.4?mg was the most cost-effective treatment alternative compared with D&E or orlistat alone, and extendedly dominated other pharmacotherapies such as NB-32 or liraglutide 3.0?mg. Results were sensitive to the inclusion of the combined benefits of mortality, cancer, CVD, and knee osteoarthritis.
- |||||||||| Promacta (eltrombopag) / Novartis
Journal: Inhibiting autophagy before it starts. (Pubmed Central) - Apr 29, 2024 We discovered a drug molecule Eltrombopag that inhibits the expression of autophagic lysosomal genes at the stage of transcriptional level, where the synthesis of these proteins has not really begun, by directly inhibiting the TFEB (transcription factor EB). This drug can improve the therapeutic effect of Temozolomide on glioblastoma treatment, further confirming the value of inhibiting autophagy in the treatment of cancer.Abbreviation: VPS34: vacuolar protein sorting 34; ULK1: unc-51 like autophagy activating kinase 1; TFEB: transcription factor EB; MITF: microphthalmia-associated transcription factor; TFE3: transcription factor E3; EO: Eltrombopag; ITC: isothermal titration calorimetry; bHLH-LZ: basic helix-loop-helix leucine zipper; LAMP1: lysosomal-associated membrane protein 1; CTSF: cathepsin F; HEXA: hexosaminidase subunit alpha.
- |||||||||| Livtencity (maribavir) / Takeda, GSK
Journal, HEOR, Cost-effectiveness, Cost effectiveness, Post-transplantation: Cost-effectiveness of maribavir versus conventional antiviral therapies for post-transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective. (Pubmed Central) - Apr 29, 2024 P3 Compared with IAT, maribavir was more cost-effective for transplant recipients with refractory CMV, owing to better clinical efficacy and avoidance of high costs associated with administration, monitoring, AEs, and hospitalizations. These results can inform healthcare decision-makers on the most effective use of their resources for post-transplant refractory CMV treatment.
- |||||||||| Review, Journal: Advancements in biologic therapy in eosinophilic asthma. (Pubmed Central) - Apr 29, 2024
Biological therapy for asthma targeting the IgE, IL-4, IL-5, IL-13, and TSLP pathways are shown to have benefit for the treatment of eosinophilic asthma, as exemplified in real world studies. When choosing the right biological agent factors such as phenotype, comorbidities, and cost-effectiveness of the biologic agent must be taken into consideration.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Journal: Trial Design for Mixed Urinary Incontinence: Midurethral Sling Versus Botulinum Toxin A. (Pubmed Central) - Apr 29, 2024 When choosing the right biological agent factors such as phenotype, comorbidities, and cost-effectiveness of the biologic agent must be taken into consideration. This trial will provide information to guide care for women with MUI refractory to oral treatment who seek surgical treatment with either onabotulinumtoxinA or MUS.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Review, Journal: Management of Hemorrhoids and Anal Fissures. (Pubmed Central) - Apr 28, 2024 In this article, the authors review each step of patient management, with emphasis on evidence-based treatment options for hemorrhoids and anal fissures. The article discusses the pathophysiology, diagnosis, medical management, and procedures for hemorrhoids followed by a detailed overview on the management of anal fissures.
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
P4 data, Journal: Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia. (Pubmed Central) - Apr 28, 2024 While rates of AEFIs was higher with HZ/su than ZVL, most AEFIs were mild and did not require medical attention. Our findings support the change in vaccine recommendations and the use of HZ/su in immunisation programs.
- |||||||||| Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
Journal: Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England. (Pubmed Central) - Apr 27, 2024 Levels of COVID-19-attributable hospitalizations and deaths were low in mAb-treated patients and among subgroups. Similar hospitalization rates were observed whilst Omicron BA.1, BA.2, and BA.5 were predominant, despite reported reductions in in vitro neutralization activity of sotrovimab against BA.2 and BA.5.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron
Journal: Multidimensional Impact of Dupilumab on Chronic Rhinosinusitis with Nasal Polyps: A Complete Health Technology Assessment of Clinical, Economic, and Non-Clinical Domains. (Pubmed Central) - Apr 27, 2024 This presents a more economical profile compared with the cost per responder for omalizumab (36.2% response rate) at 24,999EUR and mepolizumab (28.5% response rate) at 31,863EUR. These results underscore dupilumab's potential, not merely in terms of clinical outcomes, but also in terms of economic rationality, thereby solidifying its status as a valid and preferrable alternative in the management of CRSwNP, in the context of the Italian NHS.
- |||||||||| Promacta (eltrombopag) / Novartis, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Review, Journal: Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms. (Pubmed Central) - Apr 27, 2024 Recent advancements in genomic profiling have provided valuable insights into the biological underpinnings of MDSs and have expanded therapeutic options, particularly for specific molecularly defined subgroups. This review highlights the diagnostic principles, classification updates, prognostic stratification systems, and novel treatments, which could inform future clinical trials and enhance the management of adult MDS patients, particularly for specific molecularly defined subgroups.
- |||||||||| Cecolin (recombinant human papillomavirus bivalent (types 16, 18) vaccine (Escherichia coli)) / Wantai BioPharm, Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine, Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) / Merck (MSD)
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country setting. (Pubmed Central) - Apr 27, 2024 Oping for 2 doses of 9vHPV vaccine in conjunction with a primary HPV screening represents the most cost-effective option for implementing a school-based HPV vaccination program targeting 12-year-old girls in Thailand. Such findings provide valuable insights for policymakers in the realm of cervical cancer prevention.
- |||||||||| Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Ocrevus (ocrelizumab) / Roche, Biogen, Rituxan (rituximab) / Roche
Journal, Adverse events: Dental Adverse Effects of Anti-CD20 Therapies. (Pubmed Central) - Apr 26, 2024 To our knowledge, this is the first case series reporting dental conditions developed in patients long-term treated with anti-CD20 treatments. This issue, literature data, and Vigilyze
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Clinical, Observational data, Retrospective data, Journal, Real-world evidence, Real-world effectiveness, Real-world: Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study. (Pubmed Central) - Apr 26, 2024 In this exploratory analysis, anti-CGRP mAbs showed superior effectiveness for HIT-6 and ASC12 compared to BoNT-A. Reductions in terms of month headache days (MHD), migraine disability assessment test (MIDAS), and migraine acute medications (MAM) were clinically relevant for both treatments.
- |||||||||| Review, Journal: Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Drug Interactions. (Pubmed Central) - Apr 26, 2024
However, monoclonal antibodies may worsen diseases with already weakened CGRP neurotransmission, Raynaud phenomenon and constipation. Monoclonal antibodies used for prevention of migraine do not engage in significant pharmacokinetic interactions with other drugs; however, they do engage in pharmacodynamic interactions with other anti-migraine drugs, additively augmenting their prophylactic action, but also increasing frequency and severity of adverse reactions, which are a consequence of the CGRP neurotransmission interruption.
- |||||||||| Zejula (niraparib) / GSK, J&J
Journal: Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and (Pubmed Central) - Apr 26, 2024 P1 The RS-DAT met BE criteria (range 80%-125%) versus SAC based on 90% CI of GMR for Cmax,ss and AUC 0-24h,ss. The LS-DAT was considered BE to SAC on the basis of the niraparib component meeting the BE criteria in the primary analysis for AUC 0-72h; abiraterone meeting the BE criteria in additional paired analyses based on Cmax,ss and AUC 0-24h,ss; and the percentage of simulated LS-DAT versus SAC BE trials meeting the BE criteria for both.
- |||||||||| Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
Retrospective data, Journal: Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany. (Pubmed Central) - Apr 26, 2024 Retrospective cohort study of patients with COPD and ?1 prescription for single-inhaler triple therapy (SITT; fluticasone furoate/umeclidinium/vilanterol [FF/UMEC/VI] or beclomethasone dipropionate/glycopyrronium bromide/formoterol [BDP/GLY/FOR]) or multiple-inhaler triple therapy (MITT), using data from the AOK PLUS German sickness fund (1 January 2015-31 December 2019)...Overall, 97.9% of prevalent triple therapy users and 86.4% of incident triple therapy initiators received maintenance treatment in the 24-month pre-index period. In a real-world setting in Germany, triple therapy was most frequently used after maintenance therapy in patients with recent exacerbations, in line with current treatment recommendations.
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Review, Journal: The state of the art in the treatment of severe aplastic anemia: immunotherapy and hematopoietic cell transplantation in children and adults. (Pubmed Central) - Apr 26, 2024 Since 2022, horse antithymocyte globulin (hATG) has been available again in Europe and is recommended for IST as a more effective option than rabbit ATG...Despite an improved response to the new immunosuppression protocols with hATG and eltrombopag, some patients are not cured or remain at risk of aplasia relapse or clonal evolution and require postponed alloHCT...With the use of posttransplant cyclophosphamide, haploidentical HCT offers promising outcomes also in AA. In this paper, we present the state of the art in the management of severe AA for pediatric and adult patients based on the available guidelines and recently published studies.
|